Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study.


Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
01 2023
Historique:
received: 14 06 2022
revised: 25 08 2022
accepted: 25 08 2022
pubmed: 13 11 2022
medline: 24 12 2022
entrez: 12 11 2022
Statut: ppublish

Résumé

In its earliest phases, Ebola virus disease's rapid-onset, high fever, and gastrointestinal symptoms are largely indistinguishable from other infectious illnesses. We aimed to characterise the clinical indicators associated with Ebola virus disease to improve outbreak response. In this retrospective analysis, we assessed routinely collected data from individuals with possible Ebola virus disease attending 30 Ebola health facilities in two provinces of the Democratic Republic of the Congo between Aug 1, 2018, and Aug 28, 2019. We used logistic regression analysis to model the probability of Ebola infection across 34 clinical variables and four types of possible Ebola virus disease exposures: contact with an individual known to have Ebola virus disease, attendance at any funeral, health facility consultation, or consultation with an informal health practitioner. Data for 24 666 individuals were included. If a patient presented to care in the early symptomatic phase (ie, days 0-2), Ebola virus disease positivity was most associated with previous exposure to an individual with Ebola virus disease (odds ratio [OR] 11·9, 95% CI 9·1-15·8), funeral attendance (2·1, 1·6-2·7), or health facility consultations (2·1, 1·6-2·8), rather than clinical parameters. If presentation occurred on day 3 or later (after symptom onset), bleeding at an injection site (OR 33·9, 95% CI 12·7-101·3), bleeding gums (7·5, 3·7-15·4), conjunctivitis (2·4, 1·7-3·4), asthenia (1·9, 1·5-2·3), sore throat (1·8, 1·3-2·4), dysphagia (1·8, 1·4-2·3), and diarrhoea (1·6, 1·3-1·9) were additional strong predictors of Ebola virus disease. Some Ebola virus disease-specific signs were less prevalent among vaccinated individuals who were positive for Ebola virus disease when compared with the unvaccinated, such as dysphagia (-47%, p=0·0024), haematemesis (-90%, p=0·0131), and bleeding gums (-100%, p=0·0035). Establishing the exact time an individual first had symptoms is essential to assessing their infection risk. An individual's exposure history remains of paramount importance, especially in the early phase. Ebola virus disease vaccination reduces symptom severity and should also be considered when assessing the likelihood of infection. These findings about symptomatology should be translated into practice during triage and should inform testing and quarantine procedures. Médecins Sans Frontières and its research affiliate Epicentre.

Sections du résumé

BACKGROUND
In its earliest phases, Ebola virus disease's rapid-onset, high fever, and gastrointestinal symptoms are largely indistinguishable from other infectious illnesses. We aimed to characterise the clinical indicators associated with Ebola virus disease to improve outbreak response.
METHODS
In this retrospective analysis, we assessed routinely collected data from individuals with possible Ebola virus disease attending 30 Ebola health facilities in two provinces of the Democratic Republic of the Congo between Aug 1, 2018, and Aug 28, 2019. We used logistic regression analysis to model the probability of Ebola infection across 34 clinical variables and four types of possible Ebola virus disease exposures: contact with an individual known to have Ebola virus disease, attendance at any funeral, health facility consultation, or consultation with an informal health practitioner.
FINDINGS
Data for 24 666 individuals were included. If a patient presented to care in the early symptomatic phase (ie, days 0-2), Ebola virus disease positivity was most associated with previous exposure to an individual with Ebola virus disease (odds ratio [OR] 11·9, 95% CI 9·1-15·8), funeral attendance (2·1, 1·6-2·7), or health facility consultations (2·1, 1·6-2·8), rather than clinical parameters. If presentation occurred on day 3 or later (after symptom onset), bleeding at an injection site (OR 33·9, 95% CI 12·7-101·3), bleeding gums (7·5, 3·7-15·4), conjunctivitis (2·4, 1·7-3·4), asthenia (1·9, 1·5-2·3), sore throat (1·8, 1·3-2·4), dysphagia (1·8, 1·4-2·3), and diarrhoea (1·6, 1·3-1·9) were additional strong predictors of Ebola virus disease. Some Ebola virus disease-specific signs were less prevalent among vaccinated individuals who were positive for Ebola virus disease when compared with the unvaccinated, such as dysphagia (-47%, p=0·0024), haematemesis (-90%, p=0·0131), and bleeding gums (-100%, p=0·0035).
INTERPRETATION
Establishing the exact time an individual first had symptoms is essential to assessing their infection risk. An individual's exposure history remains of paramount importance, especially in the early phase. Ebola virus disease vaccination reduces symptom severity and should also be considered when assessing the likelihood of infection. These findings about symptomatology should be translated into practice during triage and should inform testing and quarantine procedures.
FUNDING
Médecins Sans Frontières and its research affiliate Epicentre.

Identifiants

pubmed: 36370717
pii: S1473-3099(22)00584-9
doi: 10.1016/S1473-3099(22)00584-9
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-102

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Auteurs

Justus Nsio (J)

General Direction of Disease Control, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Denis-Luc Ardiet (DL)

Department of Epidemiology, Intervention, and Training, Epicentre, Paris, France. Electronic address: denis.ardiet@epicentre.msf.org.

Rebecca M Coulborn (RM)

Department of Epidemiology, Intervention, and Training, Epicentre, Paris, France.

Emmanuel Grellety (E)

Department of Epidemiology, Intervention, and Training, Epicentre, Paris, France.

Manuel Albela (M)

Medical Department, Médecins sans Frontières, Geneva, Switzerland.

Francesco Grandesso (F)

Department of Epidemiology, Intervention, and Training, Epicentre, Paris, France.

Richard Kitenge (R)

National Program of Emergencies and Humanitarian Actions, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Dolla L Ngwanga (DL)

Extended Program of Immunization, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Bibiche Matady (B)

National Program of Emergencies and Humanitarian Actions, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Guyguy Manangama (G)

Department of Emergencies, Médecins sans Frontières, Paris, France.

Mathias Mossoko (M)

General Direction of Disease Control, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

John Kombe Ngwama (JK)

General Direction of Disease Control, Ministry of Health, Kinshasa, Democratic Republic of the Congo.

Placide Mbala (P)

Department of Epidemiology, Institut National de la Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo.

Francisco Luquero (F)

Department of Epidemiology, Intervention, and Training, Epicentre, Paris, France.

Klaudia Porten (K)

Department of Epidemiology, Intervention, and Training, Epicentre, Paris, France.

Steve Ahuka-Mundeke (S)

Department of Virology, Institut National de la Recherche Biomédicale (INRB), Kinshasa, Democratic Republic of the Congo; Département de Biologie Médicale, Cliniques Universitaires de Kinshasa, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH